LEO Pharma A/S

A decade ago, Almirall took the strategic decision to focus exclusively on medical dermatology, and after posting a strong set of financials for 2024, CEO Carlos Gallardo has told investors that “I’m

Leo Pharma has posted a strong set of financials for 2024, a year which saw the Danish drugmaker nail its three ambitions of increasing top-line growth, improving profitability and advancing in innova

Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the